Can a 10-Minute clock test spot Alzheimer's early?
NCT ID NCT07341009
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new tool called the CHRONOS battery to measure how people with Alzheimer's disease perceive time. Researchers want to see if this quick, 10-minute test can identify specific problems with time perception, like judging durations or remembering when events happened. The goal is to find early warning signs and improve care for people with Alzheimer's.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple test that helps doctors spot early signs of Alzheimer's and track how the disease changes a person's sense of time.
- What could go wrong
- This is a small, early-stage study with only 40 participants, so results may not apply to everyone. The tool is still experimental and not yet proven to improve diagnosis or treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2025
- Expected to finish
-
Nov 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with Alzheimer's disease
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * No objection from the participant or their legal representative, if applicable, prior to or during the assessment * Deficit in at least two cognitive functions, including episodic memory. Exclusion Criteria: * History of head trauma with loss of consciousness lasting more than 1 hour * Presence of clinically significant major psychiatric disorders (according to DSM-IV-TR criteria) * Use of medications likely to alter cognitive and/or brain function (decision by the principal investigator)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer's disease(AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Caen Hospital, neurology Unit
RECRUITINGCaen, 14000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your health Data's hidden patterns: can they predict what happens next?
- A new brain scan tracer aims to light up myelin damage
- Blood clues may unmask Alzheimer's earliest inflammatory changes
- Can a blood bank unlock the genetics of brain disease?
- Can a new PET tracer light up the protein behind some dementias and ALS?
- Can a simple blood test predict Alzheimer's years before symptoms?